745017-94-1

Product Details:

CasNo： 745017-94-1

Molecular Formula： C39H65N5O8

Appearance： White to Off-White Solid

Delivery Time： 2 weeks after order

Throughput： 100KG/Month

Purity： 99%

Synonyms: MMAF; MonoMethyl Auristatin F | MMAF; MMAF (MonoMethylauristatin F); Monomethyl auristatin phenylalanine; MONOMETHYL AURISTATIN PHENYLALANINE; (2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid; (2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid
Boiling point: 896.8±65.0 °C
Density: 1.116±0.06 g/cm3
Solubility: Soluble in DMSO
Pka: 3.56±0.10
Stability: Hygroscopic

Description:
MonoMethylauristatin F is an effective tubulin polymerization inhibitor, used as an anti-tumor drug. MMAF (Monomethylauristatin F) is widely used as the cytotoxic component of antibody-conjugated drugs (ADCs), such as Vorsetuzumab mafodotin and SGN-CD19A.

Uses: 
MonoMethylauristatin F an antimicrotubule agent. A potent mitotic inhibitor.

Biotechnological Applications:
MonoMethylauristatin F is a new auristatin derivative with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, Monomethyl auristatin E (MMAE). Because of MMAF is highly toxic, it cannot be used as a drug itself. MonoMethylauristatin F induces potent antitumor effects when conjugated via protease cleavable linkers to a monoclonal antibody targeting internalizing, tumor-specific cell surface antigens. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism.